CP-547632

DB12962InvestigationalSmall molecule

CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₀H₂₄BrF₂N₅O₃S · 532.402 g/mol (avg)
Code names: CP-547,632 · OSI-632

Resolves to

Compound

UNIIW1B375O5M2CAS252003-65-9ChEMBLCHEMBL253969PubChem9811611

Structure

InChIKeyHXHAJRMTJXHJJZ-UHFFFAOYSA-NSMILESNC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC1=C(F)C=C(Br)C=C1F

Targets

P35968KDR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with CP-547632, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account